Levialfa Infusion contains Levetiracetam 500 mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levialfa Infusion is administered intravenously, providing a rapid and effective route of delivery, particularly useful in patients unable to take oral medication or requiring prompt seizure control. The infusion should be administered over 15 minutes and can be used as monotherapy or adjunctive therapy. Dosage adjustments may be necessary in patients with renal impairment. Common adverse effects include somnolence, dizziness, headache, and fatigue, while serious reactions such as behavioral changes and hypersensitivity are less frequent but warrant close monitoring. Levialfa Infusion is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients. Caution is advised when used concomitantly with other central nervous system depressants. This formulation ensures consistent plasma levels, facilitating seizure management in acute and chronic settings. Healthcare professionals should monitor renal function and adjust dosing accordingly to optimize therapeutic outcomes.